Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biohit OyjLTS:0DRP 78 ROC (Joel Greenblatt) % is 148.27% as of Dec. 2025, which is 846% above its 10-year median of 15.67. GuruFocus rates LTS:0DRP with a GF Score™ of 78/100 and a GF Value™ of €2.71 (Fairly Valued). The stock has 4 warning signs investors should review. Among 840 Medical Devices & Instruments companies, Biohit Oyj ranks better than 98.93% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Biohit Oyj's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 148.27%.
The historical rank and industry rank for Biohit Oyj's ROC (Joel Greenblatt) % or its related term are showing as below:
LTS:0DRP'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -263.69 Med: 15.67 Max: 405.12
Current: 166.22
During the past 13 years, Biohit Oyj's highest ROC (Joel Greenblatt) % was 405.12%. The lowest was -263.69%. And the median was 15.67%.
LTS:0DRP's ROC (Joel Greenblatt) % is ranked better than 98.93% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 4.145
vs LTS:0DRP: 166.22
Biohit Oyj's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Biohit Oyj ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Biohit Oyj's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DRP vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Biohit Oyj's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 148.27% mean?
Biohit Oyj (LTS:0DRP) has a ROC (Joel Greenblatt) % of 148.27% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Biohit Oyj and its competitors. This is 846% above median its historical median of 15.67. According to the industry distribution chart, Biohit Oyj ranks #9 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 1.1%.
Is Biohit Oyj's ROC (Joel Greenblatt) % too high?
Biohit Oyj's current ROC (Joel Greenblatt) % of 148.27% is 846% above median its 10-year median of 15.67. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.15. Biohit Oyj's value of 148.27% is 3477.1% above this industry median. Based on the distribution chart, Biohit Oyj ranks #9 out of 840 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Biohit Oyj has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #9 out of 840 companies for ROC (Joel Greenblatt) %. This places Biohit Oyj in the top 1% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.15. Biohit Oyj's value of 148.27% is 3477.1% above this benchmark. While the company's 10-year median is 15.67 vs. the industry median of 4.15, Biohit Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.15, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biohit Oyj's current ROC (Joel Greenblatt) % of 148.27% is 3477.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Biohit Oyj and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biohit Oyj's current ROC (Joel Greenblatt) % is 148.27%, which is 846% above median its own 10-year median of 15.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.71, compared to a current price of €2.74 — trading 1.1% above its estimated fair value. The current ROC (Joel Greenblatt) % is 148.27%, which is 846% above median its 10-year median of 15.67 and 3477.1% above the Medical Devices & Instruments industry median of 4.15. Biohit Oyj's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current ROC (Joel Greenblatt) % is 148.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be overvalued.
The current stock price of €2.74 is trading 1.1% above its estimated GF Value™ of €2.71.
GuruFocus considers Biohit Oyj to be Fairly Valued.
Key valuation signals for LTS:0DRP:
ROC (Joel Greenblatt) %: 148.27% (846% above median its 10-year median of 15.67)
GF Value™: €2.71 vs. price of €2.74 (1.1% above fair value)
Industry Position: 3477.1% above the Medical Devices & Instruments median (#9 of 840)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
78GF Score
Get the complete analysis for LTS:0DRP
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
